选股方面，该行看好阿里健康(00241)，维持"买入"评级及目标价7.8港元；预期在创新药及医疗健康产 品增长动能持续、与阿里巴巴-W(09988)协同效应深化，以及AI应用日益普及的推动下，阿里健康2026 至2028财年的收入及经调整净利润年均复合增长率将达13%及24%。 另外，该行亦看好平安好医生(01833)，维持"买入"评级，目标价20港元；预期在与中国平安(02318)协 同效应深化，及AI持续赋能的推动下，公司2025至2027年的收入及经调整净利润年均复合增长率将达 16%及56%。 同时，该行对内地医疗板块维持"增持"评级，偏好领先的创新药企和合约研究、开发及生产组织 (CRDMO)，同时看好能够有效运用真实世界数据以优化AI算法，以提升服务质量的互联网医疗企业。 首选股份包括百济神州(06160)、信达生物(01801)、翰森制药(03692)、中国生物制药(01177)、和黄医药 (00013)、药明生物(02269)、药明康德(02359)及阿里健康。 大华继显发布研报称，内地互联网医疗领域正进入新阶段，推动力包括科技巨头加快AI创新以及国策 支持，例如北京推出的线上初诊试点计划。虽 ...

选股方面，该行看好阿里健康(00241)，维持"买入"评级及目标价7.8港元；预期在创新药及医疗健康产 品增长动能持续、与阿里巴巴-W(09988)协同效应深化，以及AI应用日益普及的推动下，阿里健康2026 至2028财年的收入及经调整净利润年均复合增长率将达13%及24%。 另外，该行亦看好平安好医生(01833)，维持"买入"评级，目标价20港元；预期在与中国平安(02318)协 同效应深化，及AI持续赋能的推动下，公司2025至2027年的收入及经调整净利润年均复合增长率将达 16%及56%。 同时，该行对内地医疗板块维持"增持"评级，偏好领先的创新药企和合约研究、开发及生产组织 (CRDMO)，同时看好能够有效运用真实世界数据以优化AI算法，以提升服务质量的互联网医疗企业。 首选股份包括百济神州(06160)、信达生物(01801)、翰森制药(03692)、中国生物制药(01177)、和黄医药 (00013)、药明生物(02269)、药明康德(02359)及阿里健康。 智通财经APP获悉，大华继显发布研报称，内地互联网医疗领域正进入新阶段，推动力包括科技巨头加 快AI创新以及国策支持，例如北京推出的 ...

24.99/30.26 亿元。医药电商业务给予26 财年3X PS，医疗健康及数字化服务业务给予26 财年6XPS，综 合来看，对应合理价值7.39 港元/股，给予"买入"评级。 风险提示。政策发展方向不确定；市场竞争超预期；开拓新品类及服务未达预期；线上平台面临与第三 方商家相关的风险。 阿里健康：自营收入增长加速，平台广告带动盈利能力持续提升。阿里健康自营业务占收入近9 成，自 营业务受原研药趋势拉动，公司持续加深与信达生物、先声药业等上游合作，截至FY26H1 的自营SKU 同比增长99%至161 万个，收入同比增长19%至143.8 亿元。公司也是国内YAU 最高和年度GMV 最大的 线上B2C 医疗健康品零售平台，与集团深入协同，广告服务框架协议的上限上修，利润端贡献将更加 显著。 AI+健康为公司带来新机遇。To C 层面，阿里健康主业有望受益于千问超级Agent。OpenAI 推出健康功 能、蚂蚁阿福用户持续增长，验证了用户对AI 健康管理的需求。千问超级Agent 的搭建和起量，未来也 有望赋能阿里健康的销量，用户在千问询问健康相关问题后，千问可相应给出药品/保健品的建议，跳 转淘宝/天猫完成 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月13日南向资金减持250.0万股阿里健康（00241.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持2806.4万股。近20个交易日中，获南向资金减持的有8天，累计净减持6291.7 万股。截至目前，南向资金持有阿里健康（00241.HK）19.73亿股，占公司已发行普通股的12.19%。 阿里健康信息技术有限公司是一家为医疗医药行业提供产业互联网解决方案的投资控股公司，是阿里巴 巴控股在大健康领域的旗舰平台。该公司主要从事发展医药健康产品销售业务，营运医药电商平台及消 费医疗服务平台，通过云计算、大数据等技术发展追溯及数字医疗及互联网医疗业务。 ...

Investment Rating - The report assigns a "Buy" rating for Alibaba Health, with a target price of HKD 7.39 per share [7]. Core Insights - The main business of Alibaba Health is experiencing accelerated growth, driven by the online penetration of innovative drugs and the integration of AI technologies, which present new opportunities for the company [7]. - The self-operated revenue of Alibaba Health has significantly increased, accounting for nearly 90% of total revenue, with a year-on-year growth of 19% to RMB 14.38 billion [7]. - The company is also the largest online B2C healthcare product retail platform in China, benefiting from deep collaboration with the Alibaba Group [7]. Summary by Sections Medical E-commerce Tracking - The online pharmacy market share is rapidly increasing, with innovative drugs driving growth. The retail pharmacy share has risen to 31.5%, while online pharmacies have reached 5.3% [14][15]. - The demand for original research drugs is increasing, with a shift towards online channels due to convenience and service [15][16]. Alibaba Health - The self-operated business is the main driver of revenue growth, with a 99% year-on-year increase in self-operated SKUs to 1.61 million [7]. - The company is enhancing its advertising capabilities, which will contribute significantly to profitability [7]. - AI technologies are expected to empower the main business, with initiatives like the "Qianwen Super Agent" and the medical AI assistant "Hydrogen Ion" app being developed [7]. Profit Forecast and Valuation - Revenue forecasts for fiscal years 2026 and 2027 are RMB 34.594 billion and RMB 38.235 billion, respectively, with adjusted net profits of RMB 2.499 billion and RMB 3.026 billion [2][7].

证券之星消息，2月12日南向资金增持735.4万股阿里健康（00241.HK）。近5个交易日中，获南向资金 增持的有5天，累计净增持3480.2万股。近20个交易日中，获南向资金增持的有13天，累计净增持1.33亿 股。截至目前，南向资金持有阿里健康（00241.HK）19.76亿股，占公司已发行普通股的12.2%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 阿里健康信息技术有限公司是一家为医疗医药行业提供产业互联网解决方案的投资控股公司，是阿里巴 巴控股在大健康领域的旗舰平台。该公司主要从事发展医药健康产品销售业务，营运医药电商平台及消 费医疗服务平台，通过云计算、大数据等技术发展追溯及数字医疗及互联网医疗业务。 ...

● 本报记者 齐金钊 亚太经合组织（APEC）第三十三次领导人非正式会议将于2026年11月在深圳举行。深圳提出，将扛起 APEC会议举办城市责任，乘势而上提升城市国际化水平和开放能级。在今年深圳两会期间，围绕 APEC会议举办的历史机遇，深圳两会代表委员们积极建言献策。 提升城市国际化水平 深圳市政府工作报告提出，深圳要坚持全球视野、中国气派、岭南风格、深圳特色，简约精彩高效服务 办好一次专业规范、成果丰硕、安全圆满的高水平盛会；充分展示热情友好、开放自信、包容大气的文 明形象，众志成城"办好APEC、当好东道主"。 深圳市政协委员张世春建议，打造国际人才服务"深圳样板"，搭建"一站式"服务平台。同时，升级智慧 便捷的"深圳服务"，优化外籍人员数字体验与交通医疗保障；强化对企业全球化发展的支撑，整合专业 资源搭建海外综合服务平台。借助APEC契机深化亚太区域合作，完善跨境金融与商事纠纷调解服务。 深圳市政协委员、深圳市柏斯工业设计有限公司总裁商剑锋认为，深圳作为"设计之都"与"科技创新中 心"，有责任在城市公共设施中作出示范。他建议，在APEC会场周边街道及交通枢纽，通过"设计+科 技"融合，打造如智能休憩 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in Alibaba Health, indicating strong investor interest in the company [1] Group 1: Investment Activity - On February 11, southbound funds increased their holdings by 3.084 million shares of Alibaba Health (00241.HK) [1] - Over the past five trading days, there have been five days of net increases, totaling 30.328 million shares [1] - In the last 20 trading days, there were 13 days of net increases, amounting to 132 million shares [1] - Currently, southbound funds hold 1.968 billion shares of Alibaba Health, representing 12.16% of the company's total issued ordinary shares [1] Group 2: Company Overview - Alibaba Health Information Technology Co., Ltd. provides industrial internet solutions for the medical and pharmaceutical industry [1] - The company is the flagship platform of Alibaba Group in the health sector, focusing on the development of pharmaceutical health product sales [1] - It operates a pharmaceutical e-commerce platform and consumer healthcare service platform, utilizing cloud computing and big data for traceability and digital healthcare [1]

Vi e w p o i n t | 05 Feb 2026 03:30:00 ET │ 42 pages China Healthcare All-Rounded To-C AI Solution Is in the Making; AliHealth Top Pick CITI'S TAKE China's AI healthcare segment is drawing market interest following the launch of OpenAI's ChatGPT Health and Ant's Afu app, as well as Hong Kong IPOs of AI drug-discovery companies. Ant Afu's evolution into a high- frequency health companion and its huge ready-made user base through AliPay position it well, in our view, to capitalize on commercialization opport ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Alibaba Health (00241.HK) by 11.662 million shares on February 9 [1] - Over the past five trading days, there were two days of net reductions in holdings by southbound funds, totaling a net decrease of 15.941 million shares [1] - In the last 20 trading days, there were 13 days of net increases in holdings by southbound funds, with a total net increase of 191 million shares [1] Group 2 - As of now, southbound funds hold 1.957 billion shares of Alibaba Health (00241.HK), accounting for 12.08% of the company's total issued ordinary shares [1] - Alibaba Health Information Technology Co., Ltd. is a holding company providing industrial internet solutions for the medical and pharmaceutical industry, serving as Alibaba Group's flagship platform in the health sector [1] - The company primarily engages in the sales of pharmaceutical health products, operates a pharmaceutical e-commerce platform, and offers consumer healthcare services, utilizing technologies such as cloud computing and big data for traceability and digital healthcare [1]